CStone Pharmaceuticals has released updated clinical data for its novel PD-1×VEGF×CTLA-4 trispecific antibody (TsAb), CS2009, showing promising anti-tumour activity and a manageable safety profile. In a global Phase I trial involving 113 patients with advanced solid tumours, the drug demonstrated efficacy across various cancer types, including a 90% objective response rate (ORR) in a small cohort of treatment-naive non-small cell lung cancer (NSCLC) patients with high PD-L1 expression. The therapy was well-tolerated, with no dose-limiting toxicities observed, and a low incidence of severe VEGF-related adverse events.

The company has also progressed the candidate into Phase II trials, with 85 patients enrolled across multiple tumour-specific cohorts. The safety data for CS2009 combined with standard chemotherapy in first-line settings has also been favourable. Based on these encouraging results, CStone plans to initiate global Phase III trials in NSCLC, colorectal cancer (CRC), and small cell lung cancer (SCLC) by the end of 2026, with more detailed data expected at major oncology conferences later this year.

According to PharmCube's NextBiopharm® database, CS2009 is being developed in a total of 13 oncology indications. Click here to request a free trial for NextBiopharm®.